Biotech Values

[biomaven0]

>>ABBV to adjust to whatever pricing scheme is out there by GILD and try to lock down a sizable minority of the market

Can you or someone else explain to me the dynamics of how, in the current US pricing environment, the slightly inferior but somewhat cheaper drug for a serious condition gains market share? I can see some HMOs like Kaiser pushing the cheaper drug, but is there going to be some other mechanism for this? I can't imagine the insurers or Medicare requiring the cheaper drug to be used unless contraindicated.

Peter